Appointments

It is expected that Jaap will lead the EMEAI division, with the goal of ‘shaping the company’s mission, vision and long-term strategy’, according to the company’s press release.

Jaap brings with him over a decade of experience, having previously worked as chief executive officer (CEO) of Immunodiagnostics Systems (IDS) since 2017. His experience spans market strategy, organisational development and regulatory compliance.

Prior to his role at IDS, Jaap has held positions at Novartis and Roche Diagnostics, where he honed his skills in strategic management and business development, particularly within the healthcare sector.

Andries Dragt, vice president of strategy and innovation at Sakura Finetek Europe, commented: “We are thrilled to welcome Jaap Stuut to Sakura Finetek Europe as our new president and general manager. Jaap's extensive experience and strategic vision make him an ideal leader to guide our company. We are confident that Sakura Finetek Europe will achieve even greater success under his leadership in the future.”